- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Patent holdings for IPC class A61K 31/41
Total number of patents in this class: 2782
10-year publication summary
|
202
|
182
|
170
|
164
|
162
|
158
|
141
|
133
|
123
|
49
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| SK Biopharmaceuticals Co., Ltd. | 273 |
77 |
| Novartis AG | 10341 |
70 |
| Merck Sharp & Dohme Corp. | 2184 |
44 |
| Bristol-myers Squibb Company | 4815 |
37 |
| Allergan, Inc. | 2204 |
33 |
| Merck Sharp & Dohme LLC | 3732 |
33 |
| The Regents of the University of California | 20587 |
24 |
| F. Hoffmann-La Roche AG | 7841 |
21 |
| Boehringer Ingelheim International GmbH | 4496 |
20 |
| Scandion Oncology A/S | 28 |
19 |
| Centre National de La Recherche Scientifique | 10895 |
15 |
| The Johns Hopkins University | 5829 |
15 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 116 |
15 |
| Bayer Pharma AG | 1025 |
14 |
| The General Hospital Corporation | 4832 |
14 |
| Boryung Pharmaceutical Co., Ltd. | 61 |
14 |
| The George Institute for Global Health | 31 |
14 |
| Theravance Biopharma R&D IP, LLC | 425 |
14 |
| AstraZeneca AB | 2828 |
13 |
| Rigel Pharmaceuticals, Inc. | 509 |
13 |
| Other owners | 2263 |